Cancer testis antigen and immunotherapy

Deepa Kolaseri Krishnadas
Fanqi Bai
Kenneth G Lucas
Department of Pediatrics, Division of Hematology/Oncology, University of Louisville, KY, USA

Abstract: The identification of cancer testis (CT) antigens has been an important advance in determining potential targets for cancer immunotherapy. Multiple previous studies have shown that CT antigen vaccines, using both peptides and dendritic cell vaccines, can elicit clinical and immunologic responses in several different tumors. This review details the expression of melanoma antigen family A, 1 (MAGE-A1), melanoma antigen family A, 3 (MAGE-A3), and New York esophageal squamous cell carcinoma-1 (NY-ESO-1) in various malignancies, and presents our current understanding of CT antigen based immunotherapy.

Keywords: cancer testis antigens, immunotherapy, vaccine

Introduction
The past two decades have witnessed major strides in the treatment of several pediatric and adult cancers, particularly with the use of multiagent chemotherapy, radiation therapy, and recently, monoclonal antibodies. Nevertheless, a subset of these patients will develop resistance to these modalities, leaving few treatment options with curative potential. In addition, patients with high risk metastatic disease continue to have dismal treatment outcomes, despite these advances. Therefore, for patients with relapsed, therapy refractory disease and tumors at high risk for recurrence, new treatment strategies are desperately needed.

Over the past two decades numerous groups have investigated immune-based therapies for patients with relapsed cancer. The success in using adoptive cellular immunotherapy to fight viral infections following allogeneic stem cell transplantation has encouraged some groups to focus their efforts on the infusion of cancer antigen specific, or otherwise activated, T lymphocytes. There is a long history of clinical investigation with cancer vaccines for a variety of malignant solid tumors. The recognition that dendritic cells (DC) play a key role in antigen presentation led to several groups using DC pulsed with cancer relevant antigens, while other groups have used whole tumor antigens or human leukocyte antigen (HLA) restricted epitopes. Several different antigens have been targeted in these strategies, most notably the cancer testis (CT) antigens. These tumor proteins are of interest since they are expressed on several malignant solid tumors, as well as some leukemias, and have a restricted pattern of expression, thereby limiting the possibility of an immune response directed against normal host tissues. These antigens can also be epigenetically upregulated on tumors following exposure to demethylating chemotherapy agents, potentially making tumors more susceptible to killing by antigen-specific T cells that have been stimulated.
following a CT antigen vaccine. In this review we will summarize past studies which target these antigens and future directions in CT antigen-based immunotherapy.

**Cancer immunotherapy**

An improved understanding of cellular immunology has helped to facilitate the rational design of cancer immunotherapy strategies. While conventional therapy such as chemotherapy and radiation are useful for the majority of patients, the use of these modalities alone may be insufficient for patients with relapsed cancer or for those who initially present with advanced disease. Chemotherapy often has limited efficacy in patients with relapsed disease, for whom intensification of conventional therapy to overcome drug resistance can lead to significant morbidity.

Immunotherapy can specifically target, or in general, modulate cellular immune responses against cancer proteins and has the potential to provide long-lasting responses. Adoptive transfer of autologous in vitro generated and expanded effector T cells is one such effective method. Initial studies in adoptive immunotherapy were performed in the allogeneic stem cell transplant setting to fight serious, potentially life-threatening viral infections, such as cytomegalovirus and Epstein–Barr virus. While adoptive immunotherapy has been largely successful against several viral infections, this approach has had limited success against cancer. The precursor frequency of cancer antigen-specific cells is very low, and the expansion of these cells requires multiple stimulations. In addition, the low avidity of expanded T cells against cancer antigens and the short life span of adoptively transferred effector T cells are practical limitations of adoptive immunotherapy. Several strategies have been developed to overcome these challenges, such as the use of chimeric antigen receptors, T cells genetically engineered to express T cell receptors (TCRs) with high affinity and specificity, and bispecific antibodies to promote T cell recognition of tumors.

Several immune evasion mechanisms pose major obstacles for the practical application of immunotherapy against cancer. Tumor cells can evade the immune system by (a) downregulating the expression of major histocompatibility complex (MHC) class I and class II molecules that are required for antigen presentation to T cells; (b) downregulating costimulatory molecules, such as CD80 and CD86, which are required for optimal activation of T cells; (c) upregulating coinhibitory molecules, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) ligands and programmed cell death ligand 1 (PD-L1), on tumor cells; and (d) recruiting regulatory T cells (Tregs) that produce immunosuppressive cytokines at the tumor site. For example, high expression of CTLA-4 has been correlated with increased T cell dysfunction in melanoma patients. CTLA-4 and programmed cell death 1 (PD-1) are expressed on activated T cells and contribute to T cell exhaustion. The upregulation and ligation of CTLA-4/PD-1 (on T cells) with CTLA-4 ligands and PD-L1 (on tumor cells) dampens effector T cell activation and negatively attenuates adaptive immune responses. Researchers have developed strategies to overcome the immunosuppressive tumor microenvironment by blocking the inhibitory pathways. Therefore antibodies blocking CTLA-4 or PD-1 on T cells can prevent the inhibitory signals typically transmitted through these receptors and prevent effector cells from entering into the exhaustion phase, thereby extending the life and function of activated T cells. It seems logical to combine genetically targeted therapies/adoptive immunotherapy with negative regulatory blockade to minimize the chances of tumor resistance and escape. Accordingly, Treg depletion followed by PD-1/PD-L1 blockade has shown some efficacy in the treatment of acute myeloid leukemia (AML). In a Phase I clinical trial of antibody-mediated PD-1 blockade, an objective response (complete response [CR] or partial response [PR]) was observed in those with non-small-cell lung cancer (NSCLC) (18%), melanoma (28%), and renal cell cancer (RCC) (27%). A similar Phase I trial using antibody-mediated blockade of PD-L1 induced durable tumor regression and prolonged stabilization of disease in patients with advanced cancers. A study has evaluated the contributions of CTLA-4 blockade on effector T cells and Treg populations in a mouse model of melanoma. It revealed that CTLA-4 blockade on effector cells significantly improves tumor protection while blockade of Tregs completely fails to enhance antitumor responses, and a concomitant blockade of both effector and Tregs leads to maximal antitumor activity. CTLA-4 blockade with ipilimumab (an anti-CTLA-4 antibody) has resulted in some clinical responses in patients with melanoma, ovarian cancer, prostate cancer, and RCC. A Phase III trial showed that ipilimumab, when given with or without a glycoprotein (gp)100 peptide vaccine, improved the overall survival to 10 months when compared to 6.4 months with gp100 alone in patients with metastatic melanoma. Several Phase II studies suggest that ipilimumab is effective in patients with melanoma and brain metastases. In a Phase II trial of ipilimumab plus fotemustine in 86 patients with advanced melanoma, of whom 20 patients had asymptomatic brain metastases at baseline, 40 of 86 (46.5%) patients in...
the study population achieved disease control similar to 10 of 20 patients (50%) with brain metastases. Furthermore, ipilimumab when combined with decarbazine improved the overall survival to 47% when compared to decarbazine alone (36%). These results suggest that blocking the immune checkpoints can improve overall survival in cancer patients.

**Cancer vaccines and immunotherapy**

The success of a cancer vaccine is dependent on the ability of a patient to mount a primary or memory immune response against cancer antigens used in the vaccine. Thus far, the majority of cancer vaccine studies have focused on patients with relapsed or therapy refractory disease, but there is a growing interest on the potential to use this approach to prevent relapse in patients who are at high risk for recurrence. Three main types of cancer vaccines that have been used in previous studies, including cellular vaccines, largely consist of DCs pulsed with cancer relevant antigens or tumor cell lysates, protein- or peptide-based vaccines, and vector-based vaccines where plasmid DNA and viral/bacterial/yeast vectors are used to deliver tumor-specific antigens. Potential problems with using whole cell lysates, peptides, or plasmid DNA approaches include the immunogenicity of the vaccine, the majority of cancer reactive T cells exist in low numbers and are difficult to expand, and that most tumors have developed multiple means to evade the immune system. Adjuvants can be used to enhance vaccine immunogenicity and thereby increase the likelihood of eliciting a T cell response. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been used as an adjuvant in several types of tumors including melanoma, colorectal carcinoma, RCC, and lymphoma. For example, an idiotypic protein vaccine together with GM-CSF resulted in complete molecular remission (by polymerase chain reaction [PCR]) in 8 of 11 lymphoma patients and tumor-specific cytotoxic CD4+ and CD8+ cells were found in 95% of the patients. DCs play a central role in initiating antitumor responses by activating innate and adaptive immune cells. Different DC subsets express distinct toll-like receptors (TLRs), such as TLRs 1 to 8, and upon stimulation, upregulate costimulatory molecules, pro-inflammatory cytokines, and chemokines which can assist in priming tumor-specific T cells. Therefore, different types of TLR agonists have been used as adjuvants along with DC-based vaccines in treating glioblastoma, breast cancer, melanoma, RCC, and leukemia. A list of clinical trials using DC as therapeutic vaccines has been detailed in a comprehensive review of cancer immunotherapy with these antigen presenting cells.

**Cancer testis antigens**

An ideal tumor antigen for immunotherapy should be (a) expressed specifically on tumor cells and not on healthy cells, (b) stably and homogenously expressed on all/majority of tumor cells, (c) vital for the existence of cancer cells, and (d) targeted by tumor antigen-specific cytotoxic T lymphocytes. Identification of such tumor antigens would enhance the success of cancer vaccines.

CT antigens are tumor proteins with a restricted pattern of expression, generally limited to germ cell and trophoblast tissue, but are also expressed in various human cancers. Their stable and specific expression on tumor cells and lack of expression on normal tissues make them an attractive target for cancer immunotherapy. Based on the frequency of CT antigen expression, Chen et al and Caballero and Chen classified certain types of cancers including melanoma, ovarian cancer, lung cancer, and bladder cancer as “CT-rich” tumors; RCC, colorectal cancer, and lymphoma/leukemia as “CT-poor” tumors; and breast cancer, bladder cancer, and prostate cancer as “CT-intermediate” tumors. CT antigens are divided into two groups: CT-X (encoded on X chromosome) and non-X CT antigens. An excellent review by Simpson et al summarizes the characteristics and functions of these two types of CT antigens.

Until 2004, there were around 40 CT antigens identified, but by 2012, the number of CT antigens identified had increased to 110. Our review will focus mainly on melanoma antigen family (MAGE)-A1, MAGE-A3, and New York esophageal squamous cell carcinoma (NY-ESO-1), three of the initially identified and most widely studied CT antigens in melanoma.

MAGE-A1 and MAGE-A3 are members of the MAGE gene family that are expressed on male germ line cells and placenta, as well as in melanoma, bladder cancer, breast cancer, prostate cancer, and NSCLC. NY-ESO-1 is another CT antigen found on several tumors, including in ovarian cancer, lung cancer, melanoma, as well as some sarcomas and neuroblastomas. Expression rates of MAGE-A1 and MAGE-A3 were 53.7% and 36.6%, respectively, in ovarian cancer. Several MAGE-A1 peptides restricted to individual HLA alleles have been reported in healthy donors. The frequency of expression of MAGE-A1 and NY-ESO-1 in bladder cancer versus liver cancer was 22% and 80% versus 80% and 29%, respectively. In pharyngeal tumors, MAGE-A and NY-ESO-1 were detectable in 70% and 33.3% of tumors, respectively. In NSCLC patients, the expression of NY-ESO-1 was only 8.3%, while its expression in synovial sarcoma was 80%, and its expression was 100% in myxoid/round cell liposarcoma patients. Screening neuroblastoma cell lines for these antigens by reverse
transcriptase-PCR (RT-PCR) has revealed that 44% are positive for MAGE-A1, 21% for MAGE-A3, and 30%–82% for NY-ESO-1, and immunohistochemical analysis has shown a good correlation between gene and protein expression. In addition, in neuroblastoma, a higher level of NY-ESO-1 expression has been reported in patients with later stage disease. The frequency of MAGE-A1 expression increased from 20% (in primary tumors) to 51% with advanced disease (in distant metastases), while NY-ESO-1 expression remained at 45%, regardless of stage of disease in melanoma patients. In malignant gammopathies, the expression pattern of MAGE-A1, MAGE-A3, and NY-ESO-1 was heterogeneous, and the expression of these antigens was greater in patients with stage III extramedullary plasmacytoma or high risk myeloma relative to low risk disease groups. This indicates that levels of expression of CT antigens vary depending upon the type of cancer and the stage of a patient’s disease, with many tumors having increased expression of CT antigens upon progression/relapse.

The expression of CT antigens on tumors has been correlated with the presence of CT antigen-specific B and T cell responses. Studies in adult patients have demonstrated that MAGE-A1 and MAGE-A3 specific T cells are present and can be augmented with a vaccine, or by stimulation of these T cells in culture. There is also a correlation between the detection of MAGE-A3 specific CD8+ T cells and regression of tumors in melanoma patients. MAGE-specific CD8+ T cell responses have been reported in AML patients. In adult T cell leukemia/lymphoma cells, NY-ESO-1 and MAGE-A3 were expressed in 61.4% and 31.6% of cells, respectively. This study detected NY-ESO-1 specific antibodies in 11.6%, and NY-ESO-1 specific CD8+ T cell responses in 55.6%, of adult T cell leukemia/lymphoma patients. Another study demonstrated CD8+ T cell responses in 10 of 11 patients with NY-ESO-1 positive melanoma who had NY-ESO-1 antibodies, but not in patients with NY-ESO-1 negative tumors or those lacking antibodies. There has also been a report on the detection of interferon-γ (IFN-γ) producing NY-ESO-1 specific T cells in neuroblastoma patients. These studies indicate that MAGE-A1, MAGE-A3, and NY-ESO-1 are immunogenic and capable of eliciting T and B cell responses.

Clinical trials have been reported using DC-based vaccines, whole protein vaccines, or HLA restricted epitopes for MAGE-A1 and MAGE-A3 positive malignancies. Chianese-Bullock et al gave vaccines consisting of MAGE-A1, MAGE-A10, and gp100 peptides with GM-CSF and incomplete Freund’s adjuvant to patients with stage IIB to IV melanoma. There were increases in MAGE-A1 specific IFN-γ production postvaccination, and cytotoxic T lymphocyte (CTL) from these patients lysed tumor cells expressing MAGE-A1. MacKensen et al reported on the results of a MAGE-A1 and MAGE-A3 peptide loaded DC vaccine in 14 melanoma patients. Clinical and immunologic responses were seen in two patients, and increased melanoma peptide specific immune responses were seen in four patients. Thurner et al reported the use of MAGE-A3 peptide pulsed mature DC at doses of 3 × 10^6 DC per vaccine, given at 14 day intervals. Significant expansion of MAGE-A3 specific CD8+ cytotoxic T cells was induced in 8 of 11 patients, with regression of individual metastases in 6 of 11 patients. The ongoing clinical trials with CT antigens, MAGE-A1, MAGE-A3, and NY-ESO-1 are presented in Table 1.

The majority of clinical trials with NY-ESO-1 tumor vaccines have used either individual HLA restricted epitopes or whole protein, with or without adjuvants. Most of these studies have demonstrated enhancement of T and B cell responses to this antigen postvaccination. Some of the initial clinical trials with NY-ESO-1 peptide vaccines used HLA-A2 restricted peptides, and demonstrated that CD8+ T cell responses can be expanded postvaccination. Bender et al used an HLA-A2 restricted NY-ESO-1 peptide for vaccination, and reported that three of nine seronegative patients developed CD8+ T cell responses. One study used full length NY-ESO-1 protein with the ISCOMATRIX™ adjuvant in 46 patients with fully resected, NY-ESO-1 positive tumors. These investigators found high titer antibody responses, as well as CD4+ and CD8+ T cell responses, against a wide range of NY-ESO-1 epitopes postvaccination. There was improved survival, with only two of 19 relapses in the group receiving adjuvant and protein, in comparison with nine of 16 relapses in the group receiving protein alone. Upon further evaluation, persisting anti-NY-ESO-1 immunity was detected in ten of 14 recipients who had previously received vaccine with ISCOMATRIX™ adjuvant, while immunity only persisted in three of 14 recipients who received vaccine alone.

**Combination therapy**

A major focus of research during the past two decades has been to identify methods to overcome the mechanisms used by tumors to evade the immune system. Different approaches including conventional therapy, molecular-targeted
Cancer testis (CT) antigen and immunotherapy

Table 1: Ongoing clinical trials with the cancer testis antigens MAGE-A1, MAGE-A3, and NY-ESO-1

<table>
<thead>
<tr>
<th>Tumor type</th>
<th>Cancer testis (CT) antigen</th>
<th>Combination</th>
<th>ClinicalTrials.gov identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuroblastoma and sarcoma</td>
<td>MAGE-A1, MAGE-A3, NY-ESO-1</td>
<td>CT antigen specific dendritic cell vaccine preceded by decitabine as a demethylating chemotherapy</td>
<td>NCT01241162</td>
</tr>
<tr>
<td>Myeloma</td>
<td>MAGE-A3</td>
<td>Combination of MAGE-A3 vaccine plus activated T cells</td>
<td>(R)</td>
</tr>
<tr>
<td>Myeloma</td>
<td>MAGE-A3, NY-ESO-1</td>
<td>CT antigen peptides in combination with DTPACE chemotherapy and auto transplantation</td>
<td>NCT00090493</td>
</tr>
<tr>
<td>Melanoma</td>
<td>NY-ESO-1b, MAGE-A10</td>
<td>Vaccine with NY-ESO-1b and MAGE-A10 and montanide, CpG and low dose IL-2</td>
<td>(R)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>NY-ESO-1</td>
<td>TLR3 agonist adjuvant and NY-ESO-1 vaccination</td>
<td>(A)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>NY-ESO-1</td>
<td>GSK2241658A antigen-specific cancer immunotherapeutic for NY-ESO-1 positive melanoma</td>
<td>NCT01213472</td>
</tr>
<tr>
<td>NY-ESO-1 expressing solid tumors</td>
<td>NY-ESO-1</td>
<td>DEC-205-NY-ESO-1 fusion protein vaccine with or without sirolimus (immunosuppressant drug) for NY-ESO-1 positive tumors</td>
<td>NCT01522820</td>
</tr>
<tr>
<td>Melanoma</td>
<td>NY-ESO-1</td>
<td>Vaccination with tumor antigenic peptides and montanide</td>
<td>(A)</td>
</tr>
<tr>
<td>Small cell lung cancer</td>
<td>NY-ESO-1, MAGE-A1</td>
<td>Chemotherapy (platinum) with immunotherapy (CT antigen pulsed dendritic cell)</td>
<td>(R)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>MAGE-A3</td>
<td>Combination immunotherapy (MAGE-A3 immunizations with Hiltonol® [Poly-I:CLC] plus transfer of vaccine-primed autologous T cells) after autologous stem cell transplantation (ASCT)</td>
<td>NCT01245673</td>
</tr>
<tr>
<td>Non-small-cell lung cancer</td>
<td>MAGE-A3</td>
<td>Chemotherapy (cisplatin and vinorelbine) with cancer immunotherapeutic GSK1572932A as adjuvant therapy for MAGE-A3 positive non-small-cell lung cancer</td>
<td>NCT00455572</td>
</tr>
<tr>
<td>Melanoma</td>
<td>MAGE-A3</td>
<td>Vaccination with melanoma tumor associated antigen (MART, MAGE-3, tyrosinase, and gp100) RNA loaded dendritic cells derived from untreated monocytes</td>
<td>NCT00672542</td>
</tr>
<tr>
<td>Melanoma</td>
<td>MAGE-A3</td>
<td>Recombinant MAGE-A3 protein combined with AS15 immunological adjuvant system (recMAGE-A3 + AS15) as an antigen-specific cancer immunotherapeutic for MAGE-A3 positive tumor</td>
<td>NCT01425749</td>
</tr>
<tr>
<td>Melanoma</td>
<td>MAGE-A3</td>
<td>Peptide vaccine (MAGE-3A1) plus galectin-3 inhibitor (GM-CT-1)</td>
<td>(R)</td>
</tr>
<tr>
<td>Synovial carcinoma</td>
<td>NY-ESO-1</td>
<td>Genetically engineered NY-ESO-1 specific (c259) T cells with chemotherapy (doxorubicin)</td>
<td>(R)</td>
</tr>
<tr>
<td>NY-ESO-1 positive metastatic tumor</td>
<td>NY-ESO-1</td>
<td>CpG 7909/montanide ISA 720 with or without cyclophosphamide in combination with either NY-ESO-1 derived peptides or the NY-ESO-1 protein for NY-ESO-1 expressing tumors</td>
<td>(A)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>NY-ESO-1</td>
<td>Topical resiquimoled and/or montanide ISA® 51 VG adjuvant for NY-ESO-1 protein vaccination</td>
<td>(A)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>MAGE-A3, NY-ESO-1</td>
<td>Cytoreductive chemotherapy followed by infusion with MAGE-A3 (A3A) or NY-ESO-1 (c259) transduced autologous T cells</td>
<td>NCT01350401</td>
</tr>
<tr>
<td>Myeloma</td>
<td>MAGE-A3, NY-ESO-1</td>
<td>Autologous T cells expressing a high affinity TCR specific for MAGE-A3 or NY-ESO-1 administered post ASCT</td>
<td>(R)</td>
</tr>
<tr>
<td>Hodgkin's or non-Hodgkin's lymphoma</td>
<td>NY-ESO-1, MAGE-A4</td>
<td>Autologous tumor-associated antigen-specific cytocotoxic T lymphocytes (primed against PRAME, SSX, MAGE-A4, NY-ESO-1, and SURVIVIN pepmix)</td>
<td>(R)</td>
</tr>
<tr>
<td>Myeloma</td>
<td>MAGE-A3</td>
<td>GSK 2132231A antigen-specific cancer immunotherapeutic as adjuvant therapy in MAGE-A3 positive melanoma</td>
<td>(A)</td>
</tr>
</tbody>
</table>

Abbreviations: A, active, not recruiting; ASCT, autologous stem cell transplantation; CT, cancer testis; R, recruiting; TCR, T cell receptor; TLR3, toll-like receptor 3; MAGE-A1, melanoma antigen family A, 1; MAGE-A3, melanoma antigen family A, 3; NY-ESO-1, New York esophageal squamous cell carcinoma; DTPACE, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide; CpG, cytosine-phosphate-guanine; IL-2: Interleukin-2; DEC-205: dendritic and epithelial cells, 205kDa; MAGE-A1, melanoma antigen family A, 1; MAGE-A3, melanoma antigen family A, 3; NY-ESO-1, New York esophageal squamous cell carcinoma; DTPACE, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide; CpG, cytosine-phosphate-guanine; IL-2: Interleukin-2; DEC-205: dendritic and epithelial cells, 205kDa; polyICLC, poly-inosinic-poly-cytidylic acid [Poly(I:C)] stabilized by lysine and carboxy methyl cellulose; MART, melanoma antigen recognized by T cells; recMAGE-A3, recombinant MAGE-A3; PRAME, preferentially expressed antigen in melanoma; SSX, synovial sarcoma X chromosome.
therapy, and immunotherapy have been combined in an attempt to improve clinical outcomes. This includes using chemotherapy and blockade of immune checkpoints, cancer vaccines and radiation therapy, cancer vaccines and chemotherapy, cancer vaccines and molecular-targeted agents, and molecular-targeted agents and blockade of immune checkpoints. Current available combinations of immunotherapy and molecular-targeted therapy for cancer treatment are summarized in a review by Vanneman and Dranoff. Depletion of Tregs in combination with a cancer vaccine is another approach. Tregs can be depleted by using anti-CD25 monoclonal antibodies and studies show that chemotherapy agents such as cyclophosphamide can deplete suppress Tregs.

Among the different approaches available, we will focus our discussion on combining immunotherapy (using CT antigens) and chemotherapy, especially on the use of decitabine (DAC) as a demethylating chemotherapeutic agent that epigenetically upregulates the expression of CT antigens, and review how CT antigens have been targeted in clinical trials.

The success of immunotherapy is largely dependent on the recognition of cancer cells expressing CT antigens by antigen-specific T cells, and this is dependent on antigen expression in the context of MHC class I and class II molecules. In cancer cells, hypermethylation of promoters leads to the downregulation of expression of CT antigens and MHC molecules, which are required for antigen presentation and recognition by antigen-specific cytotoxic T cells. Since not all tumors express CT antigens, one way to upregulate the expression of CT antigens and MHC molecules, and enhance tumor cell killing by antigen-specific cytotoxic T cells, would be to reverse hypermethylation by using demethylating agents. DAC is a potent inhibitor of DNA methylation, and the doses associated with the demethylating action of DAC are much lower than those required for cytotoxicity. Several groups have demonstrated that demethylating agents, such as DAC, upregulate the expression of MAGE-A1, MAGE-A3, and NY-ESO-1 in a number of tumor cell lines, potentially making these tumors more susceptible to MAGE-A1, MAGE-A3, and NY-ESO-1 mediated killing.

There have been several in vitro studies showing the effects of demethylating chemotherapy on the expression of CT antigens. One study demonstrated that the use of DAC could result in the restoration of MHC class I and MAGE antigens on melanoma cells. Another group demonstrated that the treatment of ovarian cancer cell lines with DAC resulted in the upregulation of MAGE-A1 and MAGE-A3 expression, as well as MHC class I molecules. Sigalotti et al treated 33 patients with AML or myelodysplastic syndrome (MDS) with DAC, and measured the expression of several CT antigens by RT-PCR. In 31 of 33 patients who had no CT antigen expression prior to treatment, de novo expression of MAGE-A1 and NY-ESO-1 was observed in all but one patient 15 days after treatment. Weber et al demonstrated that MAGE-A1 expression was upregulated on several malignant melanoma cell lines following exposure to DAC, and other studies have demonstrated that DAC can increase the expression of NY-ESO-1 on malignant glioma cell lines.

Our group recently demonstrated that the majority of neuroblastoma cell lines had increased expression of MAGE-A1, MAGE-A3, and NY-ESO-1, on both a molecular and protein level, after 5 days exposure to DAC, and that this effect was associated with enhanced tumor cell killing by CT antigen specific CTL. Uptregulation of CT antigens and enhanced killing of tumor cells following treatment with DAC by CT antigen specific T cells suggests that immunotherapy using CT antigens in combination with DAC can be a potential strategy to treat relapsed patients.

Our ongoing Phase I clinical trial combining DAC and a DC vaccine targeting MAGE-A1, MAGE-A3, and NY-ESO-1 for patients with relapsed neuroblastoma demonstrated a complete response in our first patient. The clinical outcome was correlated with a robust increase in the number of MAGE-A3 specific CD8+ and CD4+ T cells, and the patient remains disease free 1 year following his vaccination. This study indicates that a combination of demethylation-based chemotherapy followed by vaccine formulations containing CT antigens can elicit antigen-specific immune responses, potentially leading to an intensified antitumor effect.

Clinical trials are currently underway using genetically engineered NY-ESO-1 specific T cells for patients with synovial sarcoma, TCRs specific for MAGEA3/A6/B18 or NY-ESO-1/L antigen family member (LAGE) for patients with ovarian cancer, and TCRs specific for MAGE-A3 and NY-ESO-1 for patients with melanoma. Adoptive transfer of autologous T cells transduced with TCR directed against NY-ESO-1 has shown an objective clinical response in 4 of 6 patients with synovial cell sarcoma and in 5 of 11 patients with melanoma. This study demonstrated a partial response lasting 18 months in 1 of 6 patients with synovial cell sarcoma and a complete regression, that lasted over 12 months, in 2 of 11 patients with melanoma.

Conclusion

CT antigens are ideal targets for immunotherapy and success of CT antigen based immunotherapy is largely dependent on

immunotherapy, and chemotherapy, especially on the use of decitabine (DAC) as a demethylating chemotherapeutic agent that epigenetically upregulates the expression of CT antigens, and review how CT antigens have been targeted in clinical trials.

The success of immunotherapy is largely dependent on the recognition of cancer cells expressing CT antigens by antigen-specific T cells, and this is dependent on antigen expression in the context of MHC class I and class II molecules. In cancer cells, hypermethylation of promoters leads to the downregulation of expression of CT antigens and MHC molecules, which are required for antigen presentation and recognition by antigen-specific cytotoxic T cells. Since not all tumors express CT antigens, one way to upregulate the expression of CT antigens and MHC molecules, and enhance tumor cell killing by antigen-specific cytotoxic T cells, would be to reverse hypermethylation by using demethylating agents. DAC is a potent inhibitor of DNA methylation, and the doses associated with the demethylating action of DAC are much lower than those required for cytotoxicity. Several groups have demonstrated that demethylating agents, such as DAC, upregulate the expression of MAGE-A1, MAGE-A3, and NY-ESO-1 in a number of tumor cell lines, potentially making these tumors more susceptible to MAGE-A1, MAGE-A3, and NY-ESO-1 mediated killing.

There have been several in vitro studies showing the effects of demethylating chemotherapy on the expression of CT antigens. One study demonstrated that the use of DAC could result in the restoration of MHC class I and MAGE antigens on melanoma cells. Another group demonstrated that the treatment of ovarian cancer cell lines with DAC resulted in the upregulation of MAGE-A1 and MAGE-A3 expression, as well as MHC class I molecules. Sigalotti et al treated 33 patients with AML or myelodysplastic syndrome (MDS) with DAC, and measured the expression of several CT antigens by RT-PCR. In 31 of 33 patients who had no CT antigen expression prior to treatment, de novo expression of MAGE-A1 and NY-ESO-1 was observed in all but one patient 15 days after treatment. Weber et al demonstrated that MAGE-A1 expression was upregulated on several malignant melanoma cell lines following exposure to DAC, and other studies have demonstrated that DAC can increase the expression of NY-ESO-1 on malignant glioma cell lines. Our group recently demonstrated that the majority of neuroblastoma cell lines had increased expression of MAGE-A1, MAGE-A3, and NY-ESO-1, on both a molecular and protein level, after 5 days exposure to DAC, and that this effect was associated with enhanced tumor cell killing by CT antigen specific CTL. Uptregulation of CT antigens and enhanced killing of tumor cells following treatment with DAC by CT antigen specific T cells suggests that immunotherapy using CT antigens in combination with DAC can be a potential strategy to treat relapsed patients.

Our ongoing Phase I clinical trial combining DAC and a DC vaccine targeting MAGE-A1, MAGE-A3, and NY-ESO-1 for patients with relapsed neuroblastoma demonstrated a complete response in our first patient. The clinical outcome was correlated with a robust increase in the number of MAGE-A3 specific CD8+ and CD4+ T cells, and the patient remains disease free 1 year following his vaccination. This study indicates that a combination of demethylation-based chemotherapy followed by vaccine formulations containing CT antigens can elicit antigen-specific immune responses, potentially leading to an intensified antitumor effect.

Clinical trials are currently underway using genetically engineered NY-ESO-1 specific T cells for patients with synovial sarcoma, TCRs specific for MAGEA3/A6/B18 or NY-ESO-1/L antigen family member (LAGE) for patients with ovarian cancer, and TCRs specific for MAGE-A3 and NY-ESO-1 for patients with melanoma. Adoptive transfer of autologous T cells transduced with TCR directed against NY-ESO-1 has shown an objective clinical response in 4 of 6 patients with synovial cell sarcoma and in 5 of 11 patients with melanoma. This study demonstrated a partial response lasting 18 months in 1 of 6 patients with synovial cell sarcoma and a complete regression, that lasted over 12 months, in 2 of 11 patients with melanoma.

Conclusion

CT antigens are ideal targets for immunotherapy and success of CT antigen based immunotherapy is largely dependent on
the recognition of cancer cells expressing CT antigens by antigen-specific T cells. Combination therapy that includes a combination of different immunotherapeutic modalities, or combination of immunotherapy with DAC and/or other chemotherapy/irradiation, or both could overcome the obstacles related to effective antitumor immunity. Such a combination therapy should primarily target upregulation of CT antigen expression and pro-apoptotic molecules on tumor cells, enhance the expression of MHC class I and class II molecules and costimulatory molecules on antigen presenting cells, and downregulate the expression of coinhibitory molecules on the surface of T cells. A combination therapy using agents to target all three types of cells could result in an antitumor immune response, and further studies addressing issues of cell dosage, timing, and necessary sequence of agents used could improve clinical outcomes.

Disclosure

The authors report no conflicts of interest in this work.

References


